Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cellectar Biosciences, Inc.CLRB · Entity 7572 | Chief Financial Officer | January 25, 2022 | January 27, 2022 |
| FEMASYS INCFEMY · Entity 7510 | Chief Financial Officer | August 07, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cellectar Biosciences, Inc.
Report date January 25, 2022 · Filed January 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.55 · Expires 2032-01-25 | Direct | 422,000 |
Reported balance
After 2022-01-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-25 · Grant · Acquired 422,000 · Balance 422,000 F1: This option shall vest over a period of three years from the grant date, with 1/3 vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest over a period of three years from the grant date, with 1/3 vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date.
FEMASYS INC
Report date August 07, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,625 |
Reported balance
After 2026-08-07 transaction · row 1
1 source rowRow 1 · 2026-08-07 · Purchase · Acquired 15,625 · Balance 15,625 F1: The purchase price paid by the reporting person for the Shares was $3.20 per share pursuant to the Securities Purchase Agreement, dated as of August 7, 2026, by and among Femasys Inc. and the purchasers party thereto. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $2.95 · Expires 2029-08-10 | Direct | 15,625 |
Reported balance
After 2026-08-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-07 · Grant · Acquired 15,625 · Balance 15,625 F2: Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions. F4: The reported securities were purchased by the reporting person for an aggregate amount of $50,000. F3: The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market. |
| Common Stock Purchase Warrant (Milestone)SEC Table II · derivative / convertible security · Conversion / exercise price $2.95 | Direct | 15,625 |
Reported balance
After 2026-08-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-07 · Grant · Acquired 15,625 · Balance 15,625 F2: Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions. F4: The reported securities were purchased by the reporting person for an aggregate amount of $50,000. F5: The Common Warrant (Milestone) is exercisable only from and after the Milestone Date, being the first date on or after August 10, 2027 on which both (i) the Company has achieved U.S. revenue of $1,500,000 for any fiscal quarter, as reported in a Form 10-Q or Form 10-K, and (ii) the volume-weighted average price of the Common Stock has satisfied certain price conditions specified in the warrant. The warrant expires on the earlier of (i) three years after the effective date of a registration statement registering the resale of the Warrant Shares and (ii) 45 days after the Company delivers notice that the Milestone Date has occurred. As of the date of this report, neither the Milestone Date nor the expiration date is determinable. F3: The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market. |
Filing footnotes · ownership attribution and instrument terms
F1: The purchase price paid by the reporting person for the Shares was $3.20 per share pursuant to the Securities Purchase Agreement, dated as of August 7, 2026, by and among Femasys Inc. and the purchasers party thereto.
F2: Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.
F3: The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.
F4: The reported securities were purchased by the reporting person for an aggregate amount of $50,000.
F5: The Common Warrant (Milestone) is exercisable only from and after the Milestone Date, being the first date on or after August 10, 2027 on which both (i) the Company has achieved U.S. revenue of $1,500,000 for any fiscal quarter, as reported in a Form 10-Q or Form 10-K, and (ii) the volume-weighted average price of the Common Stock has satisfied certain price conditions specified in the warrant. The warrant expires on the earlier of (i) three years after the effective date of a registration statement registering the resale of the Warrant Shares and (ii) 45 days after the Company delivers notice that the Milestone Date has occurred. As of the date of this report, neither the Milestone Date nor the expiration date is determinable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2026 Filed Aug 12, 2026 00:37 UTC | FEMASYS INC FEMY · Entity 7510 | GrantCommon Stock Purchase Warrant (Milestone) · Derivative | 15,625 | Not disclosed Strike: $2.95 | Not disclosed |
DisclosureSEC source: 0001140361-26-032317 · form4.xml · derivative · entry 3 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,625 Underlying: Common stock, par value $0.001 per share · 15,625 shares Expires not disclosed F2 · derivative.exercise_price: Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions. F4 · price: The reported securities were purchased by the reporting person for an aggregate amount of $50,000. F5 · derivative.exercise_date: The Common Warrant (Milestone) is exercisable only from and after the Milestone Date, being the first date on or after August 10, 2027 on which both (i) the Company has achieved U.S. revenue of $1,500,000 for any fiscal quarter, as reported in a Form 10-Q or Form 10-K, and (ii) the volume-weighted average price of the Common Stock has satisfied certain price conditions specified in the warrant. The warrant expires on the earlier of (i) three years after the effective date of a registration statement registering the resale of the Warrant Shares and (ii) 45 days after the Company delivers notice that the Milestone Date has occurred. As of the date of this report, neither the Milestone Date nor the expiration date is determinable. F5 · derivative.expiration_date: The Common Warrant (Milestone) is exercisable only from and after the Milestone Date, being the first date on or after August 10, 2027 on which both (i) the Company has achieved U.S. revenue of $1,500,000 for any fiscal quarter, as reported in a Form 10-Q or Form 10-K, and (ii) the volume-weighted average price of the Common Stock has satisfied certain price conditions specified in the warrant. The warrant expires on the earlier of (i) three years after the effective date of a registration statement registering the resale of the Warrant Shares and (ii) 45 days after the Company delivers notice that the Milestone Date has occurred. As of the date of this report, neither the Milestone Date nor the expiration date is determinable. F3 · derivative.underlying_shares: The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market. Read SEC document |
| August 07, 2026 Filed Aug 12, 2026 00:37 UTC | FEMASYS INC FEMY · Entity 7510 | GrantCommon Stock Purchase Warrant · Derivative | 15,625 | Not disclosed Strike: $2.95 | Not disclosed |
DisclosureSEC source: 0001140361-26-032317 · form4.xml · derivative · entry 2 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,625 Underlying: Common stock, par value $0.001 per share · 15,625 shares Expires 2029-08-10 F2 · derivative.exercise_price: Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions. F4 · price: The reported securities were purchased by the reporting person for an aggregate amount of $50,000. F3 · derivative.underlying_shares: The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market. Read SEC document |
| August 07, 2026 Filed Aug 12, 2026 00:37 UTC | FEMASYS INC FEMY · Entity 7510 | PurchaseCommon Stock | 15,625 | $3.20 | $50,000.00 |
DisclosureSEC source: 0001140361-26-032317 · form4.xml · nonDerivative · entry 1 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,625 F1 · price: The purchase price paid by the reporting person for the Shares was $3.20 per share pursuant to the Securities Purchase Agreement, dated as of August 7, 2026, by and among Femasys Inc. and the purchasers party thereto. Read SEC document |
| March 19, 2026 Filed Mar 27, 2026 21:00 UTC | FEMASYS INC FEMY · Entity 7510 | GrantSeries D-1 Warrants · Derivative | 34,122 | Not disclosed Strike: $0.58 | Not disclosed |
DisclosureSEC source: 0001140361-26-011787 · form4.xml · derivative · entry 1 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,122 Underlying: Common stock, par value $0.001 per share · 34,122 shares Expires 2036-03-19 F1 · derivative.exercise_price: Holder may, at its option, exercise the Series D-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.58 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series D-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions. F3 · price: The reported securities were issued to the reporting person in a private placement as consideration in connection with that certain Omnibus Amendment and Consent Agreement, dated as of March 19, 2026 by and among the Company, the reporting person and the other parties thereto. F2 · derivative.underlying_shares: The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 22:32 UTC | FEMASYS INC FEMY · Entity 7510 | GrantRestricted Stock Units · Derivative | 169,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-006342 · form4.xml · derivative · entry 2 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,000 Underlying: Common Stock · 169,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of FEMY common stock. F3 · derivative.exercise_date: The restricted stock units fully vest on February 19, 2027, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date. F3 · derivative.expiration_date: The restricted stock units fully vest on February 19, 2027, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 22:32 UTC | FEMASYS INC FEMY · Entity 7510 | GrantRestricted Stock Units · Derivative | 173,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-006342 · form4.xml · derivative · entry 1 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,000 Underlying: Common Stock · 173,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of FEMY common stock. F2 · derivative.exercise_date: The restricted stock units vest in 4 equal annual installments beginning February 19, 2027, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date. F2 · derivative.expiration_date: The restricted stock units vest in 4 equal annual installments beginning February 19, 2027, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 22:23 UTC | FEMASYS INC FEMY · Entity 7510 | OtherSeries C-1 Warrants · Derivative | 34,122 | Not disclosed Strike: $1.10 | Not disclosed |
DisclosureSEC source: 0001140361-25-041714 · form4.xml · derivative · entry 4 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,122 Underlying: Common stock, par value $0.001 per share · 34,122 shares Expires 2035-11-07 F4 · derivative.exercise_price: Holder may, at its option, exercise the Series C-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $1.10 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series C-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions. F7 · price: The reported securities were purchased by the reporting person for an aggregate amount of $25,000. F6 · derivative.underlying_shares: The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 22:23 UTC | FEMASYS INC FEMY · Entity 7510 | OtherSeries B-1 Warrants · Derivative | 34,122 | Not disclosed Strike: $0.92 | Not disclosed |
DisclosureSEC source: 0001140361-25-041714 · form4.xml · derivative · entry 3 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,122 Underlying: Common stock, par value $0.001 per share · 34,122 shares Expires 2035-11-07 F3 · derivative.exercise_price: Holder may, at its option, exercise the Series B-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.92 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series B-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions. F7 · price: The reported securities were purchased by the reporting person for an aggregate amount of $25,000. F6 · derivative.underlying_shares: The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 22:23 UTC | FEMASYS INC FEMY · Entity 7510 | OtherSeries A-1 Warrants · Derivative | 34,122 | Not disclosed Strike: $0.81 | Not disclosed |
DisclosureSEC source: 0001140361-25-041714 · form4.xml · derivative · entry 2 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,122 Underlying: Common stock, par value $0.001 per share · 34,122 shares Expires 2035-11-07 F2 · derivative.exercise_price: Holder may, at its option, exercise the Series A-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.81 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series A-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions. F7 · price: The reported securities were purchased by the reporting person for an aggregate amount of $25,000. F6 · derivative.underlying_shares: The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 22:23 UTC | FEMASYS INC FEMY · Entity 7510 | OtherSenior Secured Convertible Notes · Derivative | Not disclosed | Not disclosed Strike: $0.73 | $25,000.00 |
DisclosureSEC source: 0001140361-25-041714 · form4.xml · derivative · entry 1 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common stock, par value $0.001 per share · 34,122 shares Expires 2035-11-07 F1 · derivative.exercise_price: Holder may, at its option, prior to maturity, convert all or any portion of the outstanding amount of Senior Secured Convertible Notes due 2035 (the "Convertible Notes"), including accrued paid in-kind interest thereon, subject to certain limitations, into shares of Common Stock, at an initial conversion price of $0.73 per share of Common Stock. The conversion rate is subject to adjustment in accordance with the terms of the Convertible Notes and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions. F7 · price: The reported securities were purchased by the reporting person for an aggregate amount of $25,000. F5 · derivative.underlying_shares: Represents the maximum number of shares of Common Stock issuable upon the voluntary conversion of the original stated amount of the Convertible Notes. The number of shares issuable upon conversion of the Convertible Notes is subject to increase in connection with the accrual of interest, which is payable in kind. The Holder's ability to convert the Convertible Notes to shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market. Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 20:37 UTC | FEMASYS INC FEMY · Entity 7510 | OtherCommon Warrants (right to buy) · Derivative | 38,828 | Not disclosed Strike: $0.52 | Not disclosed |
DisclosureSEC source: 0001140361-25-033200 · form4.xml · derivative · entry 2 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,828 Underlying: Common Stock · 38,828 shares Expires 2030-08-27 F1 · price: The reported securities are included within 38,828 Units purchased by the reporting person for $0.5151 per Unit in an underwritten public offering pursuant to the Registration Statement on Form S-1 (File No. 333-289722). Each Unit consists of one share of common stock and one warrant to purchase one share of common stock. Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 20:37 UTC | FEMASYS INC FEMY · Entity 7510 | OtherCommon Stock | 38,828 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-25-033200 · form4.xml · nonDerivative · entry 1 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,436 F1 · price: The reported securities are included within 38,828 Units purchased by the reporting person for $0.5151 per Unit in an underwritten public offering pursuant to the Registration Statement on Form S-1 (File No. 333-289722). Each Unit consists of one share of common stock and one warrant to purchase one share of common stock. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 19:51 UTC | FEMASYS INC FEMY · Entity 7510 | OtherCommon Stock | 19,608 | $1.02 | $20,000.16 |
DisclosureSEC source: 0001140361-25-021410 · form4.xml · nonDerivative · entry 1 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,608 Read SEC document |
| January 28, 2025 Filed Jan 31, 2025 00:33 UTC | FEMASYS INC FEMY · Entity 7510 | GrantStock Option (Right to Buy) · Derivative | 114,300 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001140361-25-002475 · form4.xml · derivative · entry 2 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,300 Underlying: Common Stock · 114,300 shares Expires 2035-01-28 F1 · derivative.exercise_date: The shares underlying the stock option vest equally in installments over 4 years beginning on January 28, 2025, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date. Read SEC document |
| January 28, 2025 Filed Jan 31, 2025 00:33 UTC | FEMASYS INC FEMY · Entity 7510 | GrantStock Option (Right to Buy) · Derivative | 72,045 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001140361-25-002475 · form4.xml · derivative · entry 1 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,045 Underlying: Common Stock · 72,045 shares Expires 2035-01-28 Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:43 UTC | FEMASYS INC FEMY · Entity 7510 | GrantStock Option (Right to Buy) · Derivative | 84,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001140361-24-005353 · form4.xml · derivative · entry 1 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,000 Underlying: Common Stock · 84,000 shares Expires 2034-02-01 F1 · derivative.exercise_date: The shares underlying the stock option vest equally in installments over 4 years beginning on February 1, 2024, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date. Read SEC document |
| July 03, 2023 Filed Jul 3, 2023 22:00 UTC | FEMASYS INC FEMY · Entity 7510 | GrantStock Option (Right to Buy) · Derivative | 204,700 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001140361-23-032847 · form4.xml · derivative · entry 2 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,700 Underlying: Common Stock · 204,700 shares Expires 2033-07-03 Read SEC document |
| July 03, 2023 Filed Jul 3, 2023 22:00 UTC | FEMASYS INC FEMY · Entity 7510 | GrantStock Option (Right to Buy) · Derivative | 105,200 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001140361-23-032847 · form4.xml · derivative · entry 1 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,200 Underlying: Common Stock · 105,200 shares Expires 2033-07-03 F1 · derivative.exercise_date: The shares underlying the stock option vest equally in installments over 4 years from the date of grant, assuming continued employment. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 21:38 UTC | FEMASYS INC FEMY · Entity 7510 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.97 | $0.00 |
DisclosureSEC source: 0001140361-22-007350 · form4.xml · derivative · entry 1 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-02-28 F1 · derivative.exercise_date: The shares underlying the stock option vest equally in installments over 4 years beginning on February 28, 2023, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 21:06 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 422,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001104659-22-008278 · tm224689-2_4seq1.xml · derivative · entry 1 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,000 Underlying: Common Stock · 422,000 shares Expires 2032-01-25 F1 · derivative.exercise_date: This option shall vest over a period of three years from the grant date, with 1/3 vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 22:46 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 430,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001104659-21-032853 · tm218888d4_4.xml · derivative · entry 1 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,000 Underlying: Common Stock · 430,000 shares Expires 2031-03-04 F1 · derivative.exercise_date: This option grant is a contingent grant subject to the following conditions: (i) approval by Cellectar's stockholders of shares available under Cellectar's equity incentive plans at Cellectar's 2021 annual meeting of stockholders or other special meeting of stockholders called for such purpose; and (ii) to the extent stockholder approval is received, the grant shall vest over a period of three years form the grant date, with 1/3 vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date. Read SEC document |
| December 28, 2020 Filed Dec 28, 2020 21:30 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | PurchaseCommon Stock | 7,407 | $1.35 | $9,999.45 |
DisclosureSEC source: 0001104659-20-139783 · tm2039438d1_4.xml · nonDerivative · entry 1 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,755 Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 20:08 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | PurchaseSeries H Warrants · Derivative | 2,174 | $0.01 Strike: $1.21 | $21.74 |
DisclosureSEC source: 0001104659-20-070840 · tm2022064d3_4.xml · derivative · entry 2 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,174 Underlying: Common Stock · 2,174 shares Expires 2025-06-05 Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 20:08 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | PurchaseCommon Stock | 4,348 | $1.15 | $4,978.46 |
DisclosureSEC source: 0001104659-20-070840 · tm2022064d3_4.xml · nonDerivative · entry 1 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,348 Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:02 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantCommon stock | 10,000 | $2.71 | $27,100.00 |
DisclosureSEC source: 0001104659-20-010614 · tm206696d2_4.xml · nonDerivative · entry 1 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Common stock grant that vests in equal annual increments on February 3, 2021, February 3, 2022, and February 3, 2023. Read SEC document |
| February 03, 2020 Filed Mar 5, 2020 21:02 UTC Amendment | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.71 | $0.00 |
DisclosureSEC source: 0001104659-20-029696 · tm2011832d2_4a.xml · derivative · entry 1 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-02-03 F1 · shares: This Form 4/A is being filed to correct a Form 4 filed on February 4, 2020, in which the stock option grant was reported as a common stock grant. The underlying value of the award remains unchanged. F2 · derivative.exercise_date: Stock options vest in equal annual increments on February 3, 2021, February 3, 2022, and February 3, 2023. Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 20:24 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001144204-19-044252 · tv529248_4.xml · derivative · entry 1 Elefant Dov · CIK 0001326487 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-09-10 F1 · derivative.exercise_date: Options vest in equal annual increments over a period of three years from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.